Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07424950 | Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis | PHASE2 | NOT YET_RECRUITING | 40 | — | — | Nov 1, 2026 | Nov 1, 2029 | Feb 20, 2026 | - | — |
spleen value reduction by 35%
| Arm | Type | Description |
|---|---|---|
| Bomedemstat + Momelotinib | EXPERIMENTAL | Bomedemstat + Momelotinib |
| Name | Type | Description |
|---|---|---|
| bomedemstat | DRUG | Screening (≤ 28 days) ↓ Momelotinib Alone (Weeks 0-12) * Week 12 Response Assessment If Suboptimal → Add Bomedemstat 50 mg QD Combination Phase (Weeks 12-24) ↓ Week 24 Primary Endpoint Assessment ↓ Safety Follow-Up (30 days post last dose) ↓ Long-Term Follow-Up (q12 weeks for 12 months) |
Inclusion Criteria: * 1\. Male or female participants ≥18 years of age on the day of signing informed consent. 2\. Histologically confirmed diagnosis of: * Primary Myelofibrosis (PMF), or * Secondary MF following Polycythaemia Vera (post-PV MF), or * Secondary MF following Essential Thromb...